Melanie Ott, MD, PhD

Senior Investigator, Gladstone Institute of Virology and Immunology
Professor
Department of Medicine
+1 415 734-4807
Research Overview: 

We study viruses of today to be prepared for the viruses of tomorrow. Currently, we focus on multiple human pathogens—the human immunodeficiency virus (HIV-1), Zika virus, the hepatitis B and C viruses (HBV and HCV), influenza A and B , SARS-CoV-2 and multiple common cold coronaviruses. We use four main technologies—human organoids, rapid quantitative diagnostics, a viral protein expression library, and transcriptomics. We deliberately apply lessons learned from one virus to others; specifically, we search for common host and viral factors that can be targeted by panviral therapeutics against respiratory viruses, define new ways to silence and cure chronic viral infections such as HIV and HBV and develop versatile, easy to reprogram CRISPR diagnostics that use mobile phones as readers. We welcome graduate students into our diverse and friendly research teams as equal partners and nurture their scientific success and personal growth.

Primary Thematic Area: 
Virology & Microbial Pathogenesis
Secondary Thematic Area: 
Immunology
Research Summary: 
Molecular Pathogenesis of HIV and Hepatitis C Virus Infections

Websites

Publications: 

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.

Cell

Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, Sreekumar B, Khalid MM, Ciling A, Chen PY, Kumar GR, Gliwa AS, Nguyen J, Sotomayor-Gonzalez A, Zhang Y, Frias E, Prostko J, Hackett J, Andino R, Wadford DA, Hanson C, Doudna J, Ott M, Chiu CY

Accelerating PERx Reaction Enables Covalent Nanobodies for Potent Neutralization of SARS-Cov-2 and Variants.

bioRxiv : the preprint server for biology

Yu B, Li S, Tabata T, Wang N, Kumar GR, Liu J, Ott MM, Wang L

Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system.

Open biology

Natarajan V, Simoneau CR, Erickson AL, Meyers NL, Baron JL, Cooper S, McDevitt TC, Ott M

Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination.

medRxiv : the preprint server for health sciences

Suryawanshi RK, Chen IP, Ma T, Syed AM, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, George AF, Kumar GR, Montano M, Garcia-Knight MA, Brazer N, Saldhi P, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, Fang X, Maishan M, Matthay M, Morris MK, Wadford D, Hanson C, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna J, Ott M

SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein.

bioRxiv : the preprint server for biology

Walter M, Chen IP, Vallejo-Gracia A, Kim IJ, Bielska O, Lam VL, Hayashi JM, Cruz A, Shah S, Gross JD, Krogan NJ, Schilling B, Ott M, Verdin E